课题基金 / 基金详情

Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction

Extracellular Vesicles and and HIV/cocaine associated cardiopulmonary dysfunction
细胞外囊泡和 HIV/可卡因相关的心肺功能障碍
批准号:
9204218
负责人:
Navneet Kaur Dhillon
金额:
$41.14万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-15 至 2021-05-31
关键词:
AIDS/HIV problemAnimal ModelBiological MarkersBloodBlood VesselsCardiopulmonaryCardiovascular DiseasesCardiovascular systemCell Culture SystemCellsChronicChronic Obstructive Airway DiseaseChronic lung diseaseClinicalCocaineCocaine UsersComplementCorrelative StudyDataDevelopmentDiagnosisDiseaseDisease ProgressionDrug abuseDrug userFRAP1 geneFoundationsFunctional disorderFundingFutureHIVHIV InfectionsHIV-1HealthHumanHuman immunodeficiency virus testHyperplasiaHypertrophyImmuneIn VitroIncidenceIndividualInfiltrationInflammationInflammatoryLeadLettersLightLinkLiteratureLungLung diseasesMacacaMedialMediatingMicroRNAsModelingMorbidity - disease rateMuscle functionNational Institute of Drug AbusePTEN genePathogenesisPathway interactionsPatientsPlasmaPlayPreventive InterventionPulmonary EmphysemaPulmonary HypertensionPulmonary PathologyRattusReportingResearchRisk FactorsRoleSIVSamplingSeveritiesSignal TransductionSmooth MuscleSmooth Muscle MyocytesSubstance of AbuseTestingTherapeutic InterventionTissuesTransgenic OrganismsTranslationsUp-RegulationVascular DiseasesVascular remodelingVenousViral Proteinsantiretroviral therapybaseblood vessel occlusioncell typecocaine exposuredifferential expressiondrug of abuseexosomeextracellular vesiclesheart functionin vivoinnovationinterstitialintimal medial thickeningintravenous drug usermacrophagemicrovesiclesmonocytemortalitynon-drugpressurepulmonary arterial hypertensionresponsesimian human immunodeficiency virustranscriptome sequencinguptakevesicular release

项目摘要

项目成果

Navneet Kaur Dhillon的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结: 总的来说,使用抗逆转录病毒(ART)疗法延长了艾滋病毒感染者的存活期 导致包括心肺功能障碍在内的非感染性并发症的发生率增加。 事实上,最近的报道表明,肺血管重塑和肺动脉高压(PH)先于 在HIV感染者中,呼吸道破坏/肺气肿的发展以及PH和COPD共存。 此外,静脉注射毒品被发现是个人感染艾滋病毒的最常见的危险因素。 被诊断为HIV相关PH(HRPAH)。我们之前的发现一致地表明, HIV感染静脉注射吸毒者与HIV感染非吸毒者和未感染者肺血管功能障碍的比较 静脉注射吸毒者。因此,清醒地认识到药物的滥用和艾滋病毒的感染无论是单独还是在 合并引起肺血管重塑是迫切需要的。炎症在疾病中起着至关重要的作用 与HIV感染相关的慢性肺和心血管疾病相关的血管重构。 我们早些时候在HIV感染者的肺切片中观察到了显著的血管周围炎症 猴免疫缺陷病毒(SIV)感染猕猴暴露于滥用物质包括 重塑增厚的血管内巨噬细胞数。根据我们最近的初步调查结果,我们 HIV感染和可卡因介导的巨噬细胞胞外改变的假说 小泡(EVS)通过调节血管内皮功能促进肺血管平滑肌增生和血管重塑 增殖信号在将其货物运送到平滑肌细胞时级联。这一假设将得到检验。 通过追求四个具体目标。在第一个目标中,使用RNA测序,我们将测试EV-miRNome如何获得 对HIV感染的巨噬细胞暴露于可卡因的影响。在第二个目标中,我们将评估效果 利用体外细胞培养系统对这些EV的血管平滑肌功能进行研究。第三个目标将集中在 应用HIV-TG研究EVS对肺血管重构和右心功能的影响 大鼠模型,最后在第四个目标中,我们将利用HIV感染+/-可卡因的人类样本 吸毒者将EV的变化与心肺功能障碍联系起来。这些研究具有创新性。 因为据我们所知,这将是第一次尝试理解 巨噬细胞来源的EVS以及HIV-1和可卡因介导的疾病进展。拟议的研究是 意义重大,因为这将提供一个关键的基础,以了解炎症在 HIV-1和可卡因相关心血管功能障碍的研究进展 EVS作为疾病的生物标志物和/或未来预防和治疗干预的新目标。 因此,该提案直接回应了题为“艾滋病毒/艾滋病高度优先药物滥用”的PAS-16-018号决议 研究(R01)“将由国家药物滥用研究所(NIDA)资助。
英文摘要
PROJECT SUMMARY: In general, the prolonged survival of HIV-infected patients with the use of antiretroviral (ART) therapy has resulted in an increase in the incidence of non-infectious complications including cardio-pulmonary dysfunction. In fact, recent reports suggest that pulmonary vascular remodeling and pulmonary hypertension (PH) precede the airway destruction/emphysema development and that PH and COPD coexist in HIV-infected individuals. Furthermore, IVDU has been found to be the most common risk factor of HIV-infection in the individuals diagnosed with HIV related PH (HRPAH). Our previous findings consistently suggest augmentation of pulmonary vascular dysfunction in HIV infected IVDUs compared to HIV-infected non-drug users or un-infected IVDUs . Therefore, clear understanding of how the drugs of abuse and HIV-infection either alone or in combination cause pulmonary vascular remodeling is urgently needed. Inflammation plays a crucial role in vascular remodeling associated with chronic lung and cardiovascular diseases associated with HIV-infection. We earlier observed significant perivascular inflammation in the lung sections from HIV- infected humans or simian immunodeficiency virus (SIV)-infected macaques exposed to substance of abuse including increased number of macrophages in the remodeled thickened vessels. Based on our recent preliminary findings, we hypothesize that HIV-infection and cocaine mediated alterations in the macrophage derived extracellular vesicles (EVs) promote pulmonary smooth muscle hyperplasia and vascular remodeling by regulating the proliferative signaling cascades on delivery of its cargo to smooth muscle cells . This hypothesis will be tested by pursuing four specific aims. In the first aim using RNA sequencing we will test how EV- miRnome gets influenced on exposure of HIV-infected macrophages to cocaine. In the second aim, we will evaluate the effect of these EVs on smooth muscle function using in-vitro cell-culture system. Third aim will be focused on investigating the in-vivo effect of EVs on pulmonary vascular remodeling and right heart function using HIV-Tg rat model and finally in the fourth aim we will leverage on using human samples from HIV-infected +/- cocaine abusers to correlate the changes in EVs with cardio-pulmonary dysfunction. These studies are innovative because to the best of our knowledge it will be the first attempt to understand the potential link between the macrophage derived EVs and the HIV-1 and cocaine mediated disease progression. The proposed research is significant because this will provide a critical foundation to understand the role of inflammation in the development of HIV-1 and cocaine associated cardio-vascular dysfunction while identifying specific miRNAs in EVs as biomarkers of the disease and /or new targets for preventive and therapeutic interventions in future. Therefore, the proposal is directly responsive to PAS-16-018 entitled ‘HIV/AIDS High Priority Drug Abuse Research (R01)’ to be funded by National Institute on Drug Abuse (NIDA).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drug abuse and HIV-associated pulmonary vascular injury
Drug abuse and HIV-associated pulmonary vascular injury
Drug abuse and HIV-associated pulmonary vascular injury
Drug abuse and HIV-associated pulmonary vascular injury
海外基金